SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study

NCT07307287 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

SHR-A1811
HER2-Postive Breast Cancer
HR+ Breast Cancer
Early Breast Cancer
Locally Advanced Breast Cancer

Interventions

DRUG: SHR- A1811

Sponsor

Tianjin Medical University Cancer Institute and Hospital